Cagrilintide
Cagrilintide is a synthetic analog of the human amylin hormone and functions as an amylin receptor agonist.
It is gaining attention for its effects on appetite suppression, delayed gastric emptying, and its synergy with
GLP-1 receptor agonists in the regulation of body weight and glycemic control.
Price range: $77.99 through $82.99
-
Official retailer
-
Quality guaranteed
-
Within 2 Days Delivery
-
99% Purified
Cagrilintide is a long-acting amylin analog developed to study appetite regulation, delayed gastric emptying, and energy homeostasis. As an investigational peptide, it mimics the natural hormone amylin, co-secreted with insulin from pancreatic ฮฒ-cells, and plays a critical role in postprandial glucose control and satiety signaling. Cagrilintide is often researched alone or in combination with GLP-1 analogs to investigate synergistic effects in weight regulation and metabolic syndromes.
โ Form: Lyophilized peptide
โ Purity: โฅ99%
โ Origin: Manufactured and tested in the USA
โ Certifications: Certificate of Analysis (COA) included with every order
Cagrilintide binds to amylin receptors in the brain and gastrointestinal tract, where it:
โ Slows gastric emptying to prolong digestion and nutrient absorption
โ Increases satiety signals via the area postrema in the brainstem
โ Decreases food intake and modulates caloric consumption
โ Works synergistically with GLP-1 analogs to enhance metabolic benefits
โ Amylin receptor signaling studies
โ Appetite suppression and satiety models
โ Delayed gastric emptying and gut-brain axis research
โ Obesity and weight loss combination therapies
โ Synergy studies with GLP-1 receptor agonists
โ Long-acting formulation for sustained receptor activation
โ Ideal for combination protocols with incretin-based analogs
โ Validated in animal and translational models of obesity
โ Ultra-high purity for reproducibility in controlled studies
Each vial is:
โ Manufactured in a GMP-compliant U.S. facility
โ Accompanied by a Certificate of Analysis (COA)
โ Subjected to HPLC and mass spectrometry verification
โ Shipped from within the United States for quality control
โ Contents: 5mg of lyophilized Cagrilintide peptide
โ Appearance: White/off-white powder
โ Solubility: Sterile bacteriostatic water or acetic acid recommended
โ Storage: Store lyophilized vial at -20ยฐC; reconstituted solution stable up to 30 days when refrigerated
*For laboratory research use only. Not intended for human or veterinary use.*
โ This product is sold for research purposes only
โ Not for human consumption, injection, or diagnostic procedures
โ Must be handled by qualified professionals in accordance with institutional and governmental safety guidelines
Cagrilintide is a long-acting amylin analog used in research to explore its effects on appetite regulation, gastric emptying, and body weight modulation. It mimics the endogenous hormone amylin, which is co-secreted with insulin from pancreatic beta cells.
Cagrilintide binds to the amylin receptor complex (calcitonin receptor + RAMP proteins), influencing satiety signals in the brain. Research shows it slows gastric emptying, reduces food intake, and may enhance the weight loss effects of other peptides when co-administered, particularly GLP-1 receptor agonists.
Our Cagrilintide is provided as a lyophilized powder in sterile, sealed vials for research use only. Each vial is manufactured and lab-tested in the USA to ensure purity and consistency.
No. Cagrilintide sold by Shop Peptides Direct is strictly for in vitro and in vivo laboratory research. It is not intended for human or veterinary use, and any off-label application is strictly prohibited.
Store lyophilized Cagrilintide at -20ยฐC in a desiccated environment. Once reconstituted, it should be used promptly or stored at 2โ8ยฐC and used within a limited time, depending on research protocols.
Each batch of Cagrilintide is โฅ98% pure, verified by HPLC and Mass Spectrometry. A certificate of analysis (COA) is included with every order, detailing lab testing results.
Due to its stable lyophilized form, Cagrilintide is shipped in temperature-resistant packaging. Cold-chain shipping is available for bulk or sensitive research orders upon request
Many researchers explore synergistic effects of Cagrilintide with GLP-1 agonists like Semaglutide or Tirzepatide. However, all combinatory use must be conducted within approved research protocols and settings.
You may select the product from the dropdown menu on our Lab Test Results page, enter your name and email, and weโll send the Certificate of Analysis directly to your inbox.
We deliver lab-tested, U.S.-made, and research-pure Cagrilintide with fast shipping and unmatched support. Every batch is verified for identity and integrity, ensuring your research starts with the highest-quality compound.
Cagrilintide (5 mg & 10 mg Vials) Dosage Protocol
Quickstart Highlights
Cagrilintide is a longโacting acylated analogue of the pancreatic hormone amylin, designed for onceโweekly subcutaneous administration[1]. It activates central amylin receptors to promote satiety, slow gastric emptying, and reduce food intake[2][3]. In phase 2 and phase 3 trials, cagrilintide produced doseโdependent weight loss with a predominantly gastrointestinal sideโeffect profile[4][5].
- 5 mg Vial Reconstitution: Add 3.0 mL bacteriostatic water โ ~1.67 mg/mL concentration.
- 10 mg Vial Reconstitution: Add 3.0 mL bacteriostatic water โ ~3.33 mg/mL concentration.
- Typical weekly range: 0.6โ4.5 mg once weekly (gradual titration over 4โ6 weeks).
- Easy measuring: At 1.67 mg/mL, 1 unit = 0.01 mL โ 16.7 mcg; at 3.33 mg/mL, 1 unit = 0.01 mL โ 33.3 mcg.
- Storage: Lyophilized: store frozen at โ20 ยฐC (โ4 ยฐF); after reconstitution, refrigerate at 2โ8 ยฐC (35.6โ46.4 ยฐF) and use within 30 days.
Dosing & Reconstitution Guide
Educational guide for reconstitution and weekly dosing
Standard / Gradual Approach (Both Vials)
| Week/Phase | Weekly Dose (mg) | 5 mg Vial (Units) | 10 mg Vial (Units) |
|---|---|---|---|
| Weeks 1โ2 | 0.6 mg | 36 units (0.36 mL) | 18 units (0.18 mL) |
| Weeks 3โ4 | 1.2 mg | 72 units (0.72 mL) | 36 units (0.36 mL) |
| Weeks 5โ6 | 2.4 mg | 144 units (1.44 mL) | 72 units (0.72 mL) |
| Weeks 7โ16 (Maintenance) | 4.5 mg | 270 units (2.70 mL) | 135 units (1.35 mL) |
Route: Subcutaneous injection. Frequency: Once weekly on a consistent day.
Note: Doses above 1.0 mL (100 units) require a 3 mL syringe with an appropriate subcutaneous needle (e.g., 25โ27G, ยฝโโ inch) rather than a standard Uโ100 insulin syringe. For lower starting doses (โค72 units), a Uโ100 insulin syringe provides excellent accuracy.
Reconstitution Steps (Both Vials)
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming or vigorous agitation.
- Gently swirl or roll until fully dissolved (do not shake).
- Label with date and concentration; refrigerate at 2โ8 ยฐC (35.6โ46.4 ยฐF), protected from light.
- Use within 30 days of reconstitution; discard if cloudy or particulate matter appears.
Supplies Needed
Plan based on an 8โ16 week weekly protocol with gradual titration.
For 5 mg Vials
- Peptide Vials (Cagrilintide, 5 mg each):
- 8 weeks โ 4 vials (17.4 mg total)
- 12 weeks โ 8 vials (35.4 mg total)
- 16 weeks โ 11 vials (53.4 mg total)
- Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
- 8 weeks (4 vials): 12 mL โ 2 ร 10 mL bottles
- 12 weeks (8 vials): 24 mL โ 3 ร 10 mL bottles
- 16 weeks (11 vials): 33 mL โ 4 ร 10 mL bottles
For 10 mg Vials
- Peptide Vials (Cagrilintide, 10 mg each):
- 8 weeks โ 2 vials (17.4 mg total needed)
- 12 weeks โ 4 vials (35.4 mg total needed)
- 16 weeks โ 6 vials (53.4 mg total needed)
- Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
- 8 weeks (2 vials): 6 mL โ 1 ร 10 mL bottle
- 12 weeks (4 vials): 12 mL โ 2 ร 10 mL bottles
- 16 weeks (6 vials): 18 mL โ 2 ร 10 mL bottles
Common Supplies (Both)
- Syringes:
- Weeks 1โ6 (doses โค72 units): Uโ100 insulin syringes work well
- Weeks 7+ (doses >100 units): 3 mL syringes with 25โ27G subcutaneous needles
- Per week: 1 syringe
- 8 weeks: 8 syringes
- 12 weeks: 12 syringes
- 16 weeks: 16 syringes
- Alcohol Swabs: One for the vial stopper + one for the injection site each week.
- Per week: 2 swabs
- 8 weeks: 16 swabs
- 12 weeks: 24 swabs
- 16 weeks: 32 swabs โ recommend 1 ร 100โcount box
Protocol Overview
Concise summary of the onceโweekly regimen.
- Goal: Support satiety, reduce food intake, and promote weight management over time[2][4].
- Schedule: Weekly subcutaneous injections for 12โ16 weeks (or longer as appropriate).
- Dose Range: 0.6โ4.5 mg weekly with gradual titration every 2 weeks.
- Reconstitution: 3.0 mL per vial for practical volume measurements.
- Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freezeโthaw cycles.
Dosing Protocol
Suggested weekly titration approach based on clinical trial designs[1][6].
- Start: 0.6 mg weekly for the first 2 weeks to assess tolerability.
- Escalate: Double the dose every 2 weeks (0.6 โ 1.2 โ 2.4 โ 4.5 mg) as tolerated.
- Target: 4.5 mg weekly by Weeks 7โ8; maintain at this dose.
- Frequency: Once per week (subcutaneous) on the same day each week.
- Timing: Any consistent time; rotate injection sites.
Storage Instructions
Proper storage preserves peptide integrity and potency.
- Lyophilized: Store at โ20 ยฐC (โ4 ยฐF) in dry, dark conditions; minimize moisture exposure.
- Reconstituted: Refrigerate at 2โ8 ยฐC (35.6โ46.4 ยฐF); use within 30 days and avoid freezeโthaw cycles.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Important Notes
Practical considerations for consistency and tolerability.
- Use new sterile syringes for each injection; dispose in a sharps container.
- Rotate injection sites (abdomen, thighs, upper arms) weekly to reduce local irritation.
- Gradual dose escalation minimizes gastrointestinal side effects such as nausea[4][6].
- Document weekly dose, injection site, and any adverse effects to maintain consistency.
- For maintenance doses requiring >1.0 mL, ensure you have appropriately sized syringes (3 mL).
- For โค10-unit (โค0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability.
How This Works
Cagrilintide is an acylated, longโacting analogue of amylinโa hormone coโsecreted with insulin from pancreatic beta cells[2][7]. Native amylin promotes satiation, slows gastric emptying, and inhibits postprandial glucagon secretion[8][9]. By acting on central amylin receptors (particularly in the area postrema and hindbrain), cagrilintide reduces appetite and energy intake[3][10]. Lipid modifications extend its halfโlife to approximately 160โ195 hours, enabling onceโweekly dosing[6][11].
Potential Benefits & Side Effects
Observations from phase 2 and phase 3 clinical trials.
- Weight reduction: In the phase 2 trial, cagrilintide 4.5 mg weekly produced approximately 10.8% body weight loss over 26 weeks versus 3.0% with placebo[4].
- Combination therapy: When combined with semaglutide 2.4 mg (CagriSema), phase 3 REDEFINE trials showed approximately 20% weight loss at 68 weeks, exceeding results with either agent alone[5][12].
- Doseโdependent efficacy: Higher doses (2.4โ4.5 mg) demonstrate greater weight loss than lower doses (0.3โ1.2 mg)[4].
- Side effects: Primarily gastrointestinalโnausea, vomiting, diarrhea, and constipationโwhich are generally mildโtoโmoderate and transient[4][5]. Gradual titration helps minimize these effects.
- Injectionโsite reactions: Occasional mild redness or irritation at subcutaneous injection sites.
Lifestyle Factors
Complementary strategies for optimal outcomes.
- Pair with a balanced, proteinโforward diet tailored to individual energy needs.
- Combine resistance training and aerobic activity to support metabolic health and preserve lean mass.
- Prioritize adequate sleep (7โ9 hours) and stress management for adherence and recovery.
- Monitor hydration and electrolytes, especially if experiencing gastrointestinal side effects.
Injection Technique
General subcutaneous guidance from clinical bestโpractice resources[13][14].
- Clean the vial stopper and skin with alcohol; allow to air dry completely.
- Pinch a skinfold; insert the needle at 45โ90ยฐ into subcutaneous tissue[13].
- Do not aspirate for subcutaneous injections; inject slowly and steadily.
- Hold for 5โ10 seconds before withdrawing the needle to ensure complete delivery.
- Rotate sites systematically (abdomen, thighs, upper arms) each week to avoid lipohypertrophy[14].
Recommended Source
We recommend Shop Peptides Direct for highโpurity Cagrilintide (5 mg & 10 mg).
Why Shop Peptides Direct?
- Highโpurity, thirdโpartyโtested lots with batch COAs.
- Consistent, ISOโaligned handling and documentation.
- Reliable fulfillment to maintain coldโchain integrity.
Important Note
This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. Cagrilintide is for research use only. Not for human consumption. Always consult with qualified professionals before starting any peptide research protocol.
References
-
The Lancet (2021) โ Onceโweekly cagrilintide for weight management: phase 2 doseโfinding trial (Lau et al.)
-
Int J Mol Sci (2024) โ Amylin, another important neuroendocrine hormone for treatment of diabesity
-
PMC (2022) โ Mediators of amylin action in metabolic control
-
The Lancet (2021) โ Cagrilintide phase 2 trial: 10.8% weight loss at 4.5 mg dose over 26 weeks
-
N Engl J Med (2025) โ REDEFINE 1: Coadministered cagrilintide and semaglutide in adults with overweight or obesity
-
The Lancet (2021) โ Cagrilintide + semaglutide phase 1b trial: safety, tolerability, pharmacokinetics (Enebo et al.)
-
J Med Chem (2021) โ Development of cagrilintide: a longโacting amylin analogue
-
Brain Res Rev (2005) โ Pancreatic amylin as a centrally acting satiating hormone
-
PMC (2006) โ Pancreatic signals controlling food intake: insulin, glucagon, and amylin
-
PMC (2016) โ Amylinโmediated control of glycemia, energy balance, and cognition
RELATED PRODUCTS
Retatrutide
View Certificate
5-Amino-1MQ
Tesofensine
MOTS-c
View Certificate
Reviews
There are no reviews yet.